(Q34019169)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23407561%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

title

Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23407561%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23407561%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

16

Fadlo R Khuri

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23407561%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

Suresh S Ramalingam

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23407561%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Madhusmita Behera

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23407561%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Janakiraman Subramanian

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23407561%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Nabil F Saba

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23407561%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Scott A Kono

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23407561%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Anthony A Gal

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23407561%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Gabriel Sica

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23407561%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

R Donald Harvey

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23407561%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Zhengjia Chen

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23407561%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Carmen M Klass

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23407561%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Dong M Shin

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23407561%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Haian Fu

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23407561%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Shi-yong R Sun

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23407561%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Ramaswamy Govindan

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23407561%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

publication date

1 March 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23407561%20AND%20SRC:MED&resulttype=core&format=json

Journal of Thoracic Oncology

23 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23407561%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23407561%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23407561%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

369-372

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23407561%20AND%20SRC:MED&resulttype=core&format=json

Effects of the combination of RAD001 and docetaxel on breast cancer stem cells

23 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126230

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126230

Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126230

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126230

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126230

RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126230

Targeting mTOR signaling for lung cancer therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126230

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126230

Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126230

10.1097/JTO.0B013E318282709C

29 October 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23407561%20AND%20SRC:MED&resulttype=core&format=json

release_mktoc5nkzndqvlaxvhwpoh6pa4

23 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mktoc5nkzndqvlaxvhwpoh6pa4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23407561%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

PubMed publication ID

23407561

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23407561%20AND%20SRC:MED&resulttype=core&format=json